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Dynamics of Injectable
Contraceptive Use in India
Quality of care received and interim results
three months after first injection
KEY RECOMMENDATIONS
Disseminate messaging about potential side effects of the injectable, including amenorrhea or
other changes to menstruation
The findings demonstrate a need to provide information about side effects to clients. In particular, providers
and accredited social health activists (ASHA) should inform women that amenorrhea is a potential side effect
and alleviate any concerns related to fertility. Furthermore, social behavioral change programs may consider
including specific messaging on injectables and amenorrhea in addition to other common side effects.
Institutionalize quality of care in pre-service trainings for all family planning providers and
frontline health workers
To improve quality of care during family planning visits for all contraceptive methods, providers and frontline health workers should receive training focusing on all four domains of quality of care: 1) respectful
care, 2) counseling to enable appropriate method selection, 3) counseling on effective use of method
chosen, and 4) information on continuation of contraceptive use and care. Particularly for injectable users,
many did not want any more children so there is an opportunity to counsel them on a range of methods
that include long-acting and permanent methods.
Engage husbands of recent adopters of contraception
Most women who discontinued the injectable spoke to their husband about their desire to stop using the
method. The advice given by most of these husbands was to stop using the method and only seven percent
suggested switching to another modern method. As women are going to their husbands for support, there
is an opportunity to improve continuation and switching to a modern method if husbands are equipped
with relevant information.
Train frontline health workers to visit recent injectable adopters to answer and address
concerns about injectable side effects, and counsel women on method switching
Frontline health workers can play a key role in promoting modern method switching among recent adopters
of the injectable who are dissatisfied with the method. ASHAs should visit all women who are using the
injectable to a) understand their concerns with the method, b) understand their fertility desires, and c) help
them manage any side effects they might experience. They should also encourage those who want to stop
the injectable but continue preventing pregnancy to switch to another suitable method.

Box 1

INDIA CONTRACEPTIVE USE DYNAMICS LONGITUDINAL STUDY METHODS
Through the Evidence Project, Population Council
researchers are conducting a longitudinal study
of 2,699 married women aged 15-49 who began
using IUD/PPIUD, injectable, or oral contraceptive
pill (OCP). These reversible contraceptive users are
first being interviewed within one month of starting
the method (known as the enrollment survey) and at
3-, 6- and 12-months follow-up. Respondents from
Haryana and Odisha states in India were enrolled into
the study from December 2016 to October 2017 (see
Map 1). In Haryana, all respondents were recruited
through accredited social health activists (ASHAs) at
the community level. In Odisha, PPIUD users were
recruited at government health facilities, interval
IUD and OCP users were recruited primarily through
ASHAs, and injectable users were recruited primarily
at non-governmental organization (NGO) facilities.
The purpose of this research study is to provide
evidence that can be used to strengthen the family
planning program and meet the needs of reversible
contraceptive users who want to prevent pregnancy
in India. With support from USAID/India, Population
Council researchers are exploring contraceptive use
dynamics of married women by conducting a cohort
study with the following research objectives:

Enrollment

Month 3

Month 6

BACKGROUND
Injectable contraceptive methods (DMPA and
Net-En) have been approved for private sector provision in India since 1993 (FHI, 2010). However, a
very small proportion of women use injectables:
injectable use among currently married women has
remained low over time at less than 0.05 percent in
1992-93, 0.1 percent in 2005-06, and 0.2 percent in
2015-16 (IIPS, 1995; IIPS and Macro International,
2007; IIPS and ICF, 2017). In 2016, injectables were
included in India’s National Family Planning Program
with the introduction of Antara, a brand of DMPA,
a three-month progestin-only injectable contraceptive (MOHFW, 2016b). Under Mission Parivar Vikas
(Family Development Mission), the Antara program
rolled out injectables to the sub-center level in priority districts (identified as having a total fertility rate of
at least three children per woman), and at medical
colleges and district hospitals in all states (MOHFW,
2016a, MOHFW, 2017a, MOHFW, 2017b). Through
the introduction of Antara, the Indian Government is
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1.

To assess one-year modern spacing contraceptive
discontinuation rates by modern spacing methods
(postpartum IUD/interval IUD, injectables, OCPs)
among a cohort of modern spacing contraceptive
users.

2.

To measure influencing facilitators for contraceptive continuation and discontinuation, including
intensity of experienced side effects.

3.

To measure the Method Information Index (MII)
that measures client’s recall of counseling information received.

4.

To assess influencing factors that
lead to contraceptive switching or
non-switching.

5.

To explore providers’ attitudes
about contraceptive
discontinuation
and switching, and
their practices with
clients who want
to discontinue or
switch.

Map 1
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increasing its basket of method choice in an effort to
achieve its FP2020 goals.
Given that roll out of the injectable is ongoing
throughout India, it is important to understand the
experiences of current injectable users. This brief
describes the characteristics of a sample of injectable users in India, reported quality of care they
received at the time of first injection (this study did
not observe providers during counseling interactions), contact with frontline health workers, and
continuation three months after initial injection.
Briefs focusing on oral contraceptive pills and IUD/
PPIUD are available as well (see Box 1) but are not
the focus of this brief.

METHODS
Box 1 presents the methodology of the longitudinal
study of reversible contraceptive users in India. Of
2,699 users enrolled into the study, 581 were injectable users and are the focus of this brief.

RESULTS
BACKGROUND CHARACTERISTICS
The median age of injectable users enrolled in this
study was 28 years, with a range from 18 to 46 years.
Nearly half of respondents had attended secondary
school or higher (46%), while 30 percent had never
attended school (Figure 1). Two-thirds of respondents
were Hindu (67%) and one-third were Muslim (32%).
Most respondents were homemakers (94%), two
percent were teachers/clerks and two percent were
factory/production workers. While all respondents
were married, about nine percent were not living with
their husband at the time of the enrollment survey.
Fifty-four percent owned mobile phones.

percent had two children, and 36 percent had three
or more. More than three-quarters of respondents did
not want any children in the future (Figure 2, 78%).
Twelve percent wanted to wait more than two years
before having a child, six percent wanted to wait one
to two years, one percent wanted a child within the
next year, and four percent were undecided.
Figure 2

Percent distribution of injectable users by fertility
preferences at enrollment (n=581)

Figure 1

Background characteristics of injectable users (n=581)

QUALITY OF CARE RECEIVED
Forty-six percent of respondents received their first
administration of the injectable at an NGO clinic.
Thirty-seven percent received their first injection
from a government health facility, 11 percent from a
medical store, 4 percent from a private facility, and 2
percent from a frontline health worker. Figure 3 presents 22 items measuring quality of care received
during this visit. These measures of quality are
broken down into four domains of process quality
(Jain, Townsend & Ramarao 2018): 1) respectful
care, 2) method selection, 3) effective use of the
selected method, and 4) continuity of contraceptive
use and care (see Box 2).

Two-thirds of injectable users in this sample (69%)
had used contraception in the past. Among those
who reported previously using a method (n=424),
the most recently used methods were the OCP
(32%), condoms (27%), abstinence (10%), withdrawal (10%), injectables (10%), IUD (5%), rhythm
method (4%), female condoms (1%), lactational
amenorrhea method (1%), or the emergency contraceptive pill (1%). The median age at first contraceptive use was 24 years. (Data not shown).
Nearly all injectable users had at least one living child
(over 99%). One-quarter had one child (25%), 39

Respectful care
Injectable users reported high levels of respectful
care at initial visit. Nearly all women reported a)
being treated well or very well by the provider (99%),
b) that their questions were answered to their satisfaction (98%), and c) that they were allowed to ask
questions (92%). Most felt that others couldn’t hear
(87%) or see (82%) them during their visit, and that
their information would be kept confidential (86%).
Method selection
The majority of injectable users reported that their
provider asked their preferred family planning
method (86%), their desire for another child (85%),
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Box 2

What is quality of care?
Measures of quality are broken down into four
domains of process quality (Jain et al., 2018):
1. Respectful care: Concerns interpersonal
interactions between the provider and client and
assesses aspects of privacy and confidentiality.
2. Method selection: Questions focus on information
that a provider should seek to enable appropriate
method selection at the decision-making point.
3. Effective use of the selected method: Information
given to the respondent about the method
selected.
4. Continuity of contraceptive use and care: Includes
follow-up appointments and the ability to change
methods.
Figure 3

and their preferred timing of next child (80%).
Slightly fewer were asked about their previous family
planning experience (72%), and two-thirds were
told about other methods (66%). Only 40 percent
received information about methods that protect
against STIs and 38 percent received information
without any method being strongly encouraged.

Effective use of selected method
Most respondents were told how to use the method
(92%) while only two-thirds were told how the
method works (67%). Less than half of respondents
were told about both the method’s side effects as
well as what to do if they experienced side effects
(45%). Of the potential side effects of the injectable,
the most common mentioned by providers were
irregular menstruation (39%), spotting (17%), weight
gain (14%), backache (11%), and nausea (11%).
Just 43 percent were told of the warning signs of
the method.

Aspects of process quality during initial visit reported by injectable users (n=581)
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Continuity of contraceptive use and care
Four in five injectable users (81%) were told when
to return to the facility for their next injection, and
three quarters were given an appointment card for
this visit (75%). Sixty-four percent were told about
the possibility of switching to other methods if the
injectable was not suitable, while only 45 percent
were told of other sources of injectable supply.

CONTRACEPTIVE METHOD DECISION
MAKING
All respondents were asked who made the final
decision about the method they received at enrollment after discussions with the provider (Figure 4).
Among injectable users, 96 percent reported that
they were involved in the final decision: 35 percent
made the final decision by themselves, 53 percent
made the final decision together with their husband,
and eight percent made the final decision together
with their health provider. Four percent reported that
their husband, the provider, or someone else made
the final decision. Ninety-eight percent of respondents received the method that they wanted (data
not shown). Reasons why women did not get their
preferred method was not collected in this study.

midwife (ANM), and 0.3 percent had received this
information from an Anganwadi worker (AWW). In the
three months preceding the survey, 55 percent did
not meet with a frontline health worker, 9 percent
met with a frontline health worker once, 28 percent
met two to five times, and 8 percent met more than
five times. (Data not shown).
Figure 5 presents the topics discussed with frontline health workers in the three months preceding
the survey. The most commonly discussed topic was
available contraceptive methods (22%), followed by
long acting methods (15%), fertility intentions (14%),
side-effects of methods (10%), how to deal with side
effects (7%), and return to fertility (3%).

CONTRACEPTIVE USE AT THREE MONTHS
FOLLOWING INITIAL INJECTION

At enrollment, injectable users were asked about
their contact with frontline health workers. Less than
half had ever received information from a frontline
health worker (45%). Regarding information about
the injectable, 43 percent had received information
about the injectable from an ASHA, one percent had
received this information from an auxiliary nurse

Seventy-eight percent of injectable users completed
the three-month follow-up survey (n=455). Three
months after their first injection, 76 percent were
still using the injectable method. The 24 percent
that discontinued the injectable includes 8 percent
who switched to another modern method, 4 percent
who switched to a traditional method, and 11
percent who stopped contraceptive use altogether.
The modern methods switched to after the injectable were the OCP (5% of all injectable users interviewed at three-month), condom (2%), IUD (1%), and
male and female sterilization (0.2% each). Among
those who discontinued the injectable and did not
switch to another method (n=51), most still had a
need for family planning as 69 percent did not want
any children in the future and 10 percent wanted to
wait more than two years before having a child.

Figure 4

Figure 5

CONTACT WITH FRONTLINE HEALTH
WORKERS

Percent distribution of injectable users by who made the
final decision about contraceptive method (n=581)

Topics discussed with frontline health workers in the three
months preceding the survey reported by injectable users
(n=581)
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Reasons for injectable discontinuation
Respondents who discontinued the injectable (both
those who discontinued contraception altogether
and those who switched to another method, n=104)
provided one or more reasons why they discontinued the method (Figure 6). Common reasons named
were having not menstruated since starting the
method (57%), and side effects and health concerns
(33%). Other reasons mentioned were husband’s
opposition (16%), injectable use interfered with the
body’s normal processes (9%), husband not living
at home (8%), lack of access to the method/too far
(7%), mother-in-law’s opposition (5%), not having
sex (5%), and method failure/pregnancy (4%). Only
3 percent discontinued the injectable because they
wanted to become pregnant.
Figure 6

Reasons for discontinuation reported by injectable
discontinuers at three month follow-up (n=104)

Discussions about discontinuation
Among respondents who had stopped using the
injectable by three months (including those who
switched and those who discontinued contraception altogether, n=104), fifty-two percent spoke to
their husband about their desire to stop using the
method (Figure 7). Twenty-seven percent spoke to
an ASHA, 13 percent to a provider, seven percent to
their mother-in-law, two percent to a neighbor, and
one percent to a sister-in-law. Thirty-five percent of
women spoke to no one about their desire to stop
using the injectable. Respondents were also asked if
they spoke to the same provider who gave them the
injectable about stopping the method: 38 percent
spoke to the same provider and 41 percent returned
to the same facility (data not shown).
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Figure 7

Individuals with whom injectable discontinuers
discussed their desire to discontinue the method
(n=104)

Among respondents who spoke to an ASHA about
their desire to stop the method (n=28), 13 women
reported that the ASHA asked them to stop using the
method, seven reported that the ASHA gave them
medicine for side effects, and four said the ASHA
accompanied them to a health center. Three said the
ASHA counseled them about other methods and one
said the ASHA told her to switch to a different method
(data not shown). Among those who spoke to their
husband (n=54), 42 reported that their husband
asked them to stop using the injectable. Six respondents said their husband told them to see a doctor/
ASHA, four said their husband asked them to switch
to another method, one said her husband asked her
to continue the injectable and one said her husband
suggested getting medication (data not shown).
Figure 8 presents the proportion of injectable discontinuers who switched to another modern method by
whom they spoke to about their desire to discontinue. Those who spoke to an ASHA only were most
likely to switch to another modern method (57%).
Among those who spoke to both an ASHA and their
husband, 36 percent switched to another modern
method, while those who spoke to their husband
only and those who spoke to neither their husband
nor an ASHA were least likely to switch to another
modern method (28 and 25 percent, respectively).
Figure 8

Percent of injectable discontinuers who switched to a
modern method, by whom they spoke to

DISCUSSION
Understanding the experiences of the small but
growing population of women choosing the injectable is important as the Government of India continues to rollout injectable contraceptive methods in
the public sector. In this study, most injectable users
were age 20-29 years, educated, and did not want
any more children. Most were involved in the final
decision about which contraceptive method to use
after discussions with their provider. Less than half
had spoken with a frontline health worker at least
once in the three months preceding the survey.
Injectable users’ reports demonstrate mixed results
of their interactions with providers at initial visit.
Some reported aspects of quality were high, such as
items under the respectful care domain. There is an
opportunity for improvement in other domains, such
as providing important method-related information
and alternative method choices in case the injectable is not suitable. Many women discontinued the
injectable method because they had not menstruated since starting the method. Providers should
include information on amenorrhea in routine injectable counseling so potential users know to expect
this as a potential result of use.

Injectable users’ responses about their initial visit
may have recall bias, but this is likely to be minimal
as they were interviewed within one month of the
visit in which they initiated the method. Additionally,
45 percent of injectable users had received information from a frontline worker about contraceptive
methods in the three months preceding the enrollment survey, but responses about quality of care at
initiation of injectable use may not have included
this prior counseling.
Speaking to an ASHA only about the desire to
discontinue the injectable appears to have a positive effect on women’s switching behavior as fiftyseven percent of respondents who spoke to an
ASHA only switched to another modern method.
When women spoke to their husbands in addition
to an ASHA, on the other hand, the positive effect of
the ASHA on method switching was attenuated and
the proportion switching to a modern method went
down to thirty-six percent. It is therefore critical to
both ensure ASHAs are visiting new users of injectables and to equip husbands with information to
encourage their wives to switch to another modern
method of family planning in cases where the desire
to prevent pregnancy remains.

Paula Bronstein /The Verbatim Agency/Getty Images
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